Retraction
Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy
Paper Information
Record ID:
60618
Author(s):
Journal:
Publication Date:
May 12, 2017
Retraction Date:
January 15, 2025
(<1 year years ago)
Subjects:
Institutions:
- Neurological Disorders Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, PO Box 5825, Doha, Qatar
- Life Sciences Division, College of Science and Engineering, Hamad Bin Khalifa University (HBKU), Education City, Qatar Foundation, PO Box 5825, Doha, Qatar
- Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, United States
- Department of Biomedical Sciences and Neuroscience Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
- Department of Pathology, University of California, San Diego, La Jolla, CA 92093, United States
- Veterans Affairs San Diego Healthcare System, San Diego, CA 92161, United States
Countries:
Article Type:
Publisher:
Elsevier
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1016/j.nbd.2025.106788Additional Notes:
see also: https://pubpeer.com/publications/E8BFBC4D110BB705D8152DA8AAD90D
Citations (74)
74
Total Citations0
Post-Retraction74
Pre-Retraction0
Same DayOptimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders
Anne Messer, David C. Butler
Neurobiology of Disease
Open Access
Published: Oct 2019
75 citations
75 citations
1909 days before retraction
Immunotherapy in Parkinson’s disease: Current status and future directions
Diptaman Chatterjee, Jeffrey H. Kordower
Neurobiology of Disease
Open Access
Published: Aug 2019
57 citations
57 citations
1970 days before retraction
Effects of single and combined immunotherapy approach targeting amyloid β protein and α‐synuclein in a dementia with Lewy bodies–like model
Markus Mandler, Edward Rockenstein, Cassia Overk et al. (15 authors)
Alzheimer s & Dementia
Open Access
Published: Aug 2019
23 citations
23 citations
1994 days before retraction
Animal models of synucleinopathies and how they could impact future drug discovery and delivery efforts
K. A. Jellinger
Expert Opinion on Drug Discovery
Published: Jul 2019
5 citations
5 citations
2021 days before retraction
α-Synuclein pathology in Parkinson’s disease and related α-synucleinopathies
Michael X. Henderson, John Q. Trojanowski, Virginia M.‐Y. Lee
Neuroscience Letters
Open Access
Published: Jun 2019
235 citations
235 citations
2053 days before retraction
Antibodies against alpha‐synuclein: tools and therapies
Nishant N. Vaikath, Issam Hmila, Vijay Gupta et al. (6 authors)
Journal of Neurochemistry
Open Access
Published: May 2019
64 citations
64 citations
2081 days before retraction
Progress of immunotherapy of anti-α-synuclein in Parkinson’s disease
Zhipeng Wang, Ge Gao, Chunli Duan et al. (4 authors)
Biomedicine & Pharmacotherapy
Open Access
Published: May 2019
57 citations
57 citations
2085 days before retraction
<i>In vitro</i>models of synucleinopathies: informing on molecular mechanisms and protective strategies
Amir Tayaranian Marvian, David J. Koss, Farhang Aliakbari et al. (5 authors)
Journal of Neurochemistry
Open Access
Published: Apr 2019
29 citations
29 citations
2097 days before retraction
Ultrasonication-based rapid amplification of α-synuclein aggregates in cerebrospinal fluid
Keita Kakuda, Kensuke Ikenaka, Katsuya Araki et al. (18 authors)
Scientific Reports
Open Access
Published: Apr 2019
36 citations
36 citations
2105 days before retraction
α-Synuclein misfolding and aggregation: Implications in Parkinson’s disease pathogenesis
Surabhi Mehra, Shruti Sahay, Samir K. Maji
Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Published: Mar 2019
381 citations
381 citations
2141 days before retraction
Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease
Brian Spencer, Ivy Trinh, Edward Rockenstein et al. (10 authors)
Neurobiology of Disease
Open Access
Published: Mar 2019
38 citations
38 citations
2143 days before retraction
Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson’s Disease
Maria Angela Samis Zella, Judith Metzdorf, Friederike Ostendorf et al. (8 authors)
Cells
Open Access
Published: Jan 2019
38 citations
38 citations
2176 days before retraction
Effects of Novel Calpain Inhibitors in Transgenic Animal Model of Parkinson’s disease/dementia with Lewy bodies
Getaw Worku Hassen, Leo Kesner, Alfred Stracher et al. (10 authors)
Scientific Reports
Open Access
Published: Dec 2018
24 citations
24 citations
2217 days before retraction
Emerging Immunotherapies for Parkinson Disease
Samis Zella, Judith Metzdorf, Emine Çiftçi et al. (7 authors)
Neurology and Therapy
Open Access
Published: Dec 2018
60 citations
60 citations
2227 days before retraction
Naturally occurring autoantibodies against α-synuclein rescues memory and motor deficits and attenuates α-synuclein pathology in mouse model of Parkinson's disease
Yaru Huang, Xi-xiu Xie, Mei Ji et al. (10 authors)
Neurobiology of Disease
Published: Nov 2018
26 citations
26 citations
2244 days before retraction
Recent progress of drug nanoformulations targeting to brain
Abdur Rauf Khan, Xiaoye Yang, Manfei Fu et al. (4 authors)
Journal of Controlled Release
Published: Oct 2018
187 citations
187 citations
2290 days before retraction
Paper citing Differential effects of immunotherapy with antibod...
Unknown Authors
Unknown Journal
Published: Aug 2018
2338 days before retraction
Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation
Changyoun Kim, Brian Spencer, Edward Rockenstein et al. (13 authors)
Molecular Neurodegeneration
Open Access
Published: Aug 2018
138 citations
138 citations
2351 days before retraction
Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson’s disease model
Diptaman Chatterjee, Mansi A. Bhatt, David Butler et al. (7 authors)
npj Parkinson s Disease
Open Access
Published: Jul 2018
83 citations
83 citations
2367 days before retraction
Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy
Martin Kallab, Marcos Herrera-Vaquero, Malin Johannesson et al. (9 authors)
Frontiers in Neuroscience
Open Access
Published: Jul 2018
33 citations
33 citations
2387 days before retraction
Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy
Julia E. Gerson, Kathleen Farmer, Natalie Henson et al. (8 authors)
Molecular Neurodegeneration
Open Access
Published: Mar 2018
67 citations
67 citations
2498 days before retraction
A refined concept: α-synuclein dysregulation disease
Hideki Mochizuki, Chi‐Jing Choong, Eliezer Masliah
Neurochemistry International
Open Access
Published: Jan 2018
32 citations
32 citations
2570 days before retraction
Multiple system atrophy: experimental models and reality
Cassia Overk, Edward Rockenstein, Elvira Valera et al. (6 authors)
Acta Neuropathologica
Open Access
Published: Oct 2017
21 citations
21 citations
2644 days before retraction
A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies
Jess-Karan S. Dhillon, Cara J. Riffe, Brenda D. Moore et al. (7 authors)
PLoS ONE
Open Access
Published: Sep 2017
47 citations
47 citations
2680 days before retraction
Quick Stats
Total Citations:
74
Years Since Retraction:
<1 year
Open Access:
Yes
Last Checked:
Jul 24, 2025